Priovant Initiates Phase 3 BEACON+ Trial of Brepocitinib in Cutaneous Sarcoidosis Following Breakthrough Therapy Designation
核心洞察
Priovant has enrolled the first patients in the global Phase 3 BEACON+ study evaluating brepocitinib 45 mg once daily versus placebo in approximately 140 patients with cutaneous sarcoidosis (搜索) across roughly 70 sites.
The Phase 3 trial follows positive Phase 2 results where 77% of brepocitinib-treated patients achieved a ≥50% reduction in CSAMI-A score compared to 0% on placebo, earning FDA Breakthrough Therapy Designation.
Cutaneous sarcoidosis (搜索) affects approximately 40,000 U.S. adults, disproportionately impacts Black Americans, and currently has no FDA-approved therapies despite risk of permanent scarring and tissue destruction.
Priovant Therapeutics (搜索) has enrolled the first patients in its Phase 3 BEACON+ study, evaluating the investigational dual TYK2 (搜索)/JAK1 (搜索) inhibitor brepocitinib in adults with cutaneous sarcoidosis (搜索) (CS), the company announced on August 6, 2026. The global registrational trial follows the positive Phase 2 BEACON study—the first placebo-controlled trial to demonstrate efficacy in CS—which earned brepocitinib FDA Breakthrough Therapy Designation for this indication.
BEACON+ will be conducted as a Part B to the Phase 2 BEACON trial, enrolling approximately 140 patients across roughly 70 sites worldwide. Participants will be randomized in a 3:2 ratio to receive either brepocitinib 45 mg once daily or placebo. The primary endpoint is the proportion of patients achieving a 50% or greater reduction in the Cutaneous Sarcoidosis (搜索) Activity and Morphology Instrument – Activity Score (CSAMI-A) at Week 16.
In the Phase 2 study, 77% of patients receiving brepocitinib 45 mg met this endpoint, compared to 0% of patients in the placebo arm. Topline data from BEACON+ is anticipated in calendar year 2028.
A Disease with No Approved Therapies
Cutaneous sarcoidosis (搜索) is an inflammatory granulomatous skin disease affecting approximately 40,000 adults in the United States, with a disproportionate burden among Black Americans. Unlike many inflammatory skin conditions, inadequately treated CS can rapidly lead to permanent scarring and destruction of bone, cartilage, and hair follicles. Despite the significant morbidity and risk of irreversible tissue damage, no FDA-approved therapies currently exist for this condition.
"Our vision is to establish brepocitinib as a leading treatment option across multiple rare diseases with high patient burden and few or no alternative therapies," said Ben Zimmer, Priovant CEO. "The potential upcoming approval and launch of brepocitinib in dermatomyositis (搜索) later this quarter would be an important milestone toward that vision. We are equally committed to rapidly advancing brepocitinib's development across multiple additional diseases where patients have a similar urgent need for new treatment options, and the initiation of our CS Phase 3 study reflects that commitment."
Expanding Orphan Disease Pipeline
With BEACON+ now underway, brepocitinib's orphan disease development program spans four indications with ongoing or successfully completed registrational trials. In dermatomyositis (搜索) (DM), the New Drug Application is under Priority Review at the FDA, with a PDUFA date later this quarter following the positive Phase 3 VALOR readout. In non-infectious uveitis (搜索) (NIU), the Phase 3 CLARITY trial is expected to read out later this year. Priovant is also actively enrolling a Phase 2/3 study evaluating brepocitinib in lichen planopilaris (搜索) (LPP).
All four indications share a common profile: high disease burden, risk of permanent organ damage if left untreated, and few or no FDA-approved therapies.
Mechanism of Action
Brepocitinib is a first-in-class, selective inhibitor of TYK2 (搜索) and JAK1 (搜索). Through dual TYK2/JAK1 inhibition, the oral therapy distinctively suppresses key cytokines implicated in autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with once-daily dosing. Priovant Therapeutics (搜索) is a Roivant (搜索) (Nasdaq: ROIV) company.